8-K filing — Traws Pharma, Inc. (TRAW)
Filed: 2026-10-23 AccNo: 0001104659-26-118519 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Traws Pharma Q2 EPS $(0.16) Beats $(0.34) Estimate
Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.34) by 51.52 percent. This is a 45.45 percent decrease over losses of $(0.11) per share from the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Why INLIF Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
INLIF shares jumped 78% after H1 FY26 revenue rose 26%, gross profit surged 159% and net income turned positive; other premarket movers varied.
HC Wainwright & Co. Reiterates Neutral on Traws Pharma, Maintains $1 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Traws Pharma (NASDAQ:TRAW) with a Neutral and maintains $1 price target.